BPH Management in Primary Care

Initial Evaluation and Risk Stratification

The American Urological Association guidelines recommend that primary care physicians use the International Prostate Symptom Score (IPSS/AUA Symptom Score) to categorize symptom severity: mild (<7), moderate (8-19), or severe (≥20) 1
Primary care should assess symptom bother, as patients with severe symptoms who are not bothered should not receive active treatment 1, 2
Prostate-specific antigen (PSA) testing is recommended to assess cancer risk and predict disease progression 3

For patients with mild symptoms (AUA Score <7) or non-bothersome symptoms of any severity, watchful waiting is the standard approach with annual follow-up 1, 2
The American Urological Association recommends that patients with bothersome moderate symptoms (AUA Score 8-19) be treated with alpha-blockers as first-line therapy 1
For patients with enlarged prostates (>40ml or PSA >1.5 ng/mL), 5-alpha reductase inhibitors (finasteride 5mg daily, dutasteride) are recommended to shrink prostate volume and prevent disease progression 3

Primary care must refer patients with absolute indications for surgery, such as refractory urinary retention, recurrent urinary tract infections, or renal insufficiency due to BPH, to urology 3, 4
Patients with large post-void residual volumes (>300-350ml) or upper tract dilatation should be referred to urology for further evaluation 1, 3, 4

For patients on alpha-blockers, treatment response should be assessed at 2-4 weeks after initiation, and patients should be monitored for orthostatic hypotension and dizziness 4
For patients on 5-alpha reductase inhibitors, effectiveness should be assessed at minimum 3 months, with maximum benefit at 12 months, and patients should be counseled about potential sexual side effects 4
Annual follow-up for stable patients should include repeat symptom score assessment and monitoring for disease progression or complications 3, 4

The American Urological Association recommends that primary care physicians not delay evidence-based medical therapy for patients with BPH symptoms, as this can allow disease progression and potential complications 1, 2
Patients with non-bothersome symptoms should not be treated, regardless of severity, as treatment risks outweigh benefits 1, 2

The American Urological Association and European Association of Urology guidelines recommend using treatments with a strong evidence base for clinical effectiveness, which excludes saw palmetto based on current evidence, for men with bothersome lower urinary tract symptoms (LUTS) 5
Alpha-blockers (alfuzosin, tamsulosin) are recommended as first-line therapy for symptom relief in men over 50 with bothersome LUTS 5, 6
5-alpha reductase inhibitors (finasteride, dutasteride) are recommended for men with enlarged prostates to reduce prostate volume and prevent progression, based on evidence from the American Urological Association and European Association of Urology guidelines 5, 6

Combination therapy (alpha-blocker plus 5-ARI) is recommended for patients with moderate-to-severe symptoms and prostate enlargement, addressing both dynamic and static components of obstruction, according to the European Association of Urology guidelines 7
The American Urological Association advises against delaying evidence-based medical therapy while patients trial saw palmetto, as this allows disease progression and potential complications, including acute urinary retention 8, 9